Breadcrumb

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

About

The Developmental Therapeutics Branch advances novel therapeutic strategies and conducts clinical trials based on cancer-specific genomic, epigenetic and metabolic alterations, drug design, molecular mechanisms of drug action to achieve precision medicine. The branch integrates both basic and translational science programs. The basic program focuses on cancer-specific genomic and epigenomic alterations, oxidative signaling, molecular pharmacology and drug resistance. The translational clinical program focuses on novel therapeutic agents across a spectrum of diseases and disease mechanisms. Novel therapeutic modalities are selected based on pharmacodynamic and genomic biomarkers and mechanistic hypotheses to assess clinical activity and molecular determinants of response at the early phase of drug development.

The Developmental Therapeutics Branch is organized in several research groups lead by Principal Investigators focusing on complementary areas of interest. The research laboratories and the administrative staff are located in building 37. The clinical trials are conducted at the Clinical Center in building 10.

The Developmental Therapeutics Branch includes a Genomics and Bioinformatics Group (managed by William C. Reinhold under the leadership of Dr. Yves Pommier). The Genomics and Bioinformatics Group explores the relationships between genomic alterations in malignant cells and their response to chemotherapeutic agents using molecular databases at the DNA, RNA and protein levels.

Clinical Trials

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.

News

Branch News:

Drugs Against Cancer: Stories of Discovery and the Quest for a Cure by Dr. Kurt Kohn

The Developmental Therapeutics Branch of the NCI is happy to announce the online publication of the first public version of a new book entitled "Drugs Against Cancer: Stories of Discovery and the Quest for a Cure" by Dr. Kurt Kohn, an NIH Scientist Emeritus. The aim of the book is to explain how the knowledge and application of cancer chemotherapy drugs developed. This book is an account of the earliest published work leading to the anti-cancer drug discovery and to explain how the knowledge and application of cancer chemotherapy drugs developed.

Dr. Kohn devoted nearly 60 years of his life to anti-cancer drug research at the National Cancer Institute. In the book, he wrote "I felt a responsibility to make a record of the part of the cancer drug development effort with which I was associated, going back nearly 60 years, and to relate it to the global anti-cancer drug discovery and development efforts." It is in large part a historical account, a combination of science, history, medicine, and memoir.

Chapters can be downloaded individually and new chapters are continuously added. Book chapters are available at: https://discover.nci.nih.gov/kohn-book-drugs-against-cancer.jsp

Contact

Contact Info

Center for Cancer Research National Cancer Institute

  • Building 37, Room 5068A
  • Bethesda, MD 20892-4264
  • 240-760-7317
  • 240-541-4475
Sifan Banig, B.S.
Clinical Program Coordinator (Gov.)
Sifan Banig, B.S.